All In Biotech

Drug Trial Radar · NCT02155205

A Thorough QT Study of Telotristat Etiprate

Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study

Last checked: Nov 20, 2026Latest source record: Sep 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

May 2014

Primary completion

Aug 2014

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.

Conditions

  • QT Interval

Interventions

  • Telotristat etiprateDrug

    1500 mg telotristat etiprate (six 250 mg tablets)

  • PlaceboDrug

    Matching placebo

  • MoxifloxacinDrug

    400 mg moxifloxacin (one 400 mg tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline QT interval corrected for heart rateTime frame: Days 1-3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lexicon Investigational Site

    Evansville, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.